Federal Circuit judges recently upheld a bench trial ruling from earlier this year that enables the Indian generic-drug manufacturer Lupin to market a treatment for a chronic skin condition. This decision comes in competition with a similar treatment developed by Galderma, a Swiss company known for its skincare innovations. The ruling is essential in the context of pharmaceutical patent disputes, particularly for companies looking to introduce generic alternatives into markets dominated by established, branded medications.
Read more…